Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.58	0	0	0	0
Gross Profit	0.58	0	0	0	0
Selling, General & Admin	8.43	20.97	13.55	14.93	8.59
Research & Development	7.63	16.4	23.9	37.88	20.95
Other Operating Expenses	0	76.02	0	0	0
Operating Expenses	16.06	113.39	37.45	52.81	29.54
Operating Income	-15.47	-113.39	-37.45	-52.81	-29.54
Interest Expense / Income	-1.22	-0.45	-0	-0.22	-0.16
Other Expense / Income	0.04	-0.28	-0.32	0.89	-1.33
Pretax Income	-14.29	-112.66	-37.13	-53.48	-28.06
Net Income	-14.29	-112.66	-37.13	-53.48	-28.06
Shares Outstanding (Basic)	4	2	1	1	0
Shares Outstanding (Diluted)	4	2	1	1	0
Shares Change	118.32%	55.69%	0.72%	252.08%	419.98%
EPS (Basic)	-3.95	-67.99	-34.88	-50.61	-93.40
EPS (Diluted)	-3.95	-67.99	-34.88	-50.61	-93.40
Free Cash Flow	-12.27	-25.01	-37.69	-41.83	-26.74
Free Cash Flow Per Share	-3.39	-15.09	-35.41	-39.59	-89.09
Gross Margin	100.00%	-	-	-	-
Operating Margin	-2652.80%	-	-	-	-
Profit Margin	-2449.59%	-	-	-	-
Free Cash Flow Margin	-2103.92%	-	-	-	-
EBITDA	-15.5	-112.92	-36.86	-53.47	-28.05
EBITDA Margin	-2658.27%	-	-	-	-
Depreciation & Amortization	0.01	0.19	0.27	0.23	0.17
EBIT	-15.51	-113.11	-37.13	-53.7	-28.22
EBIT Margin	-2659.48%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).